Both in Pharmaceuticals
Regeneron Pharmaceuticals vs Bristol-Myers Squibb
Over the past year REGN returned +33.8% and BMY returned +42.4%; their daily moves had a correlation of 0.40.
REGN +33.8% BMY +42.4%Growth of $1, one year, split-adjusted
| Metric | REGN | BMY |
|---|---|---|
| Price | $750.51 | $62.86 |
| Market cap | $77.27B | $128.41B |
| Today | −0.23% | −1.60% |
| 1 month | −5.5% | −5.6% |
| 6 months | +0.2% | +5.2% |
| Year to date | −2.8% | +16.5% |
| 1 year | +33.1% | +42.5% |
| Revenue growth (YoY) | +16.7% | +5.7% |
| Gross margin | 86.6% | 71.3% |
| Net margin | 30.2% | 25.6% |
| P/E (TTM) | 17.9× | 13.8× |
| Price / sales | 5.0× | 2.6× |
| Net cash | $5.29B | -$32.05B |
| Dividend yield | 0.50% | 4.01% |
| Volatility (60d) | 30.6% | 25.2% |
| Short % of float | 2.6% | 2.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).